Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-integrin alpha4 antibody
- Development stage
- Unknown
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
An anti-integrin alpha4 antibody is a monoclonal antibody designed to target and block integrin alpha-4 (ITGA4, also known as CD49d). Integrin alpha-4 forms heterodimers with beta-1 (forming VLA-4) or beta-7 integrins, which are critical for leukocyte adhesion and migration into inflamed tissues. By blocking these interactions, anti-integrin alpha4 antibodies inhibit the trafficking of inflammatory cells across the blood-brain barrier or into mucosal tissues. This mechanism makes them therapeutic candidates for autoimmune and inflammatory diseases such as multiple sclerosis, Crohn's disease, and asthma. Natalizumab is the most prominent approved clinical representative of this class.
- Other names
- anti-alpha4 integrin antibodyanti-alpha-4 integrin antibodyanti-alpha 4 integrin antibodyanti-integrin alpha-4 antibodyanti-ITGA4 antibodyanti-ITGA-4 antibodyanti-ITGA 4 antibodyintegrin alpha4 antibody
02
Targets
ITGA4 (Integrin alpha-4)α4β1 (Integrin α4β1)α4β7 (Integrin alpha-4 beta-7 heterodimer)MADCAM1 (Mucosal addressin cell adhesion molecule 1)SPP1 (Osteopontin)VCAM1 (Vascular cell adhesion molecule 1)
Beyond the preview
Go deeper on anti-integrin alpha4 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-integrin alpha4 antibody.